PedAL BCU
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, PedAL BCU sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
PedAL BCU: 3 sponsored US clinical trials, 3 recruiting.
PedAL BCU sponsors 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 1 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 2 trials.
Upper-quartile sponsor footprint
PedAL BCU sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
NCT06376162
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
NCT05183035
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
NCT04726241
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the PedAL BCU pipeline
3 recruiting of 3 indexed (100% open).
Phase mix: 1 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
PedAL BCU: open-pipeline peers nationwide
Peers matched on 3 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
PedAL BCU sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this PedAL BCU page
3 registered trials is a research-attention snapshot, not an endorsement of PedAL BCU or any single study.
- 3 of PedAL BCU's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myeloid Leukemia is the condition PedAL BCU studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. PedAL BCU pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.